根治性前列腺切除术后挽救性放疗中联合雄激素剥夺治疗及其疗程影响的系统评价与网络Meta分析
该系统评价与网络Meta分析纳入3710例前列腺癌患者,比较根治性前列腺切除术后挽救性放疗联合不同疗程雄激素剥夺治疗(ADT)对无转移生存(MFS)、无进展生存(PFS)和总生存(OS)的影响。结果显示,联合ADT显著改善MFS和PFS,且24个月疗程在MFS和PFS上最优,但对OS无显著改善;Gleason评分≥8或切缘阳性患者 from 延长ADT获益更明显。
要点
- 挽救性放疗联合ADT显著改善MFS和PFS,但对OS无显著影响。
- 24个月ADT在MFS和PFS上均优于6个月ADT和无ADT。
- Gleason评分≥8或切缘阳性患者接受24个月ADT的MFS排名最高。
核心结论
- 网络Meta分析支持挽救性放疗联合ADT,尤其是24个月疗程,可提供最佳MFS和PFS结局。
- 尽管OS未显著改善,Gleason评分≥8或切缘阳性患者仍可从延长ADT中获益。
研究设计与样本
- 系统评价与网络Meta分析,纳入RADICALS-HD、NRG/RTOG 9601、RTOG 0534、GETUG-AFU 16试验及ARTISTIC Meta分析中的三项试验(GETUG-AFU 17、RADICALS-RT、RAVES)。
- 共分析3710例前列腺癌患者数据,按ADT疗程(24个月 vs 6个月 vs 无ADT)分层,主要结局为MFS,次要结局为PFS和OS。
主要发现
- 亚组分析中,切缘阳性 and Gleason评分≥8患者接受24个月ADT的MFS排名最高。
关键数值与推荐
- ADT联合挽救性放疗显著改善MFS和PFS,与疗程无关,但对OS无显著影响。
- 24个月ADT在MFS和PFS上优于6个月ADT和无ADT。
- 切缘阳性或Gleason评分≥8患者建议优先考虑24个月ADT以优化MFS。
临床怎么用
- 对于根治性前列腺切除术后接受挽救性放疗的患者,应考虑联合ADT,尤其是24个月疗程。
- 高危患者(切缘阳性或Gleason评分≥8)从24个月ADT中获益更明显,应优先选择延长疗程。
- 与患者讨论ADT疗程时,需权衡MFS和PFS获益与OS未显著改善及潜在不良反应。
局限性
- OS未显示显著获益,可能受随访时间限制。
- 网络Meta分析基于已发表试验数据,存在间接比较的固有局限性。
- 亚组分析结果需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Recently published data comparing the impact and duration of androgen deprivation therapy (ADT) on metastasis-free survival (MFS), progression-free survival (PFS), and overall survival (OS) in patients undergoing salvage radiation therapy (sRT) after radical prostatectomy have not been compared directly; this study aims to address this knowledge gap. METHODS: We performed a systematic review and network meta-analysis (NMA) on MFS, PFS, and OS using data from the RADICALS-HD, NRG/RTOG 9601, RTOG 0534, and GETUG-AFU 16 trials, as well as three trials from the ARTISTIC meta-analysis (GETUG-AFU 17, RADICALS-RT, and RAVES) on adjuvant versus salvage radiotherapy. The primary outcome was MFS; the secondary outcomes were PFS and OS. Stratification was made according to ADT duration (ADT for 24 mo vs ADT for 6 mo vs no ADT). Subgroup analyses addressed high-risk cohorts with Gleason score ≥8 and positive surgical margins (PSMs). KEY FINDINGS AND LIMITATIONS: Data from 3710 prostate cancer patients were analyzed. Addition of ADT to sRT improved MFS and PFS significantly, regardless of the duration, but had no significant effect on OS. Hazard ratios (HRs) for ADT for 24 mo versus no ADT were 0.70 (confidence interval [CI] 0.53-0.92) for MFS, 0.51 (CI 0.43-0.61) for PFS, and 0.80 (CI 0.63-1.01) for OS; for ADT for 6 mo versus no ADT, the respective HRs were 0.79 (CI 0.65-0.97), 0.57 (CI 0.48-0.67), and 0.93 (CI 0.72-1.20). In subgroup analyses, ADT for 24 mo was ranked highest for MFS in patients with PSMs and Gleason score ≥8. CONCLUSIONS AND CLINICAL IMPLICATIONS: The NMA supports the addition of ADT to sRT, particularly a 24-mo duration, which provides the best MFS and PFS outcomes. While OS did not improve significantly, patients with Gleason score ≥8 or PSMs also benefit from prolonged ADT.
引用
- Le QC, Siech C, Hoeh B, et al. Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data. Eur Urol Oncol. 2025. PMID: 40441941. doi:10.1016/j.euo.2025.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。